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Abstract  
The United States (US) has a complex healthcare system with a mix of public, private, nonprofit, and for-profit insurers, healthcare 
institutions and organizations, and providers. Unlike other developed countries, there is not a single payer healthcare system or a 
national pharmaceutical benefits scheme/plan. Despite spending over USD 10,000 per capita in healthcare, the US is among the worst 
performers compared to other developed countries in outcomes including life expectancy at birth, infant mortality, safety during 
childbirth, and unmanaged chronic conditions (e.g., asthma, diabetes). Primary care is delivered by physicians and advanced practice 
providers (i.e., nurse practitioners and physician assistants) in a variety of settings including large health systems, federally qualified 
health centers or free clinics that provide care to the underserved, or specific facilities for veterans or American Indian and Alaska 
native peoples. Since 2010, primary care delivery has shifted toward providing patient-centered, coordinated, comprehensive care 
focused on providing proactive, rather than reactive, population health management, and on the quality, versus volume, of care. 
Community pharmacy comprises a mix of independently owned, chain, supermarket and mass merchant pharmacies. Community 
pharmacies provide services such as immunizations, medication therapy management, medication packaging, medication 
synchronization, point-of-care testing and, in specific states where legislation has been passed, hormonal contraception, opioid 
reversal agents, and smoking cessation services. There has been criticism regarding the lack of standard terminology for services such 
as medication synchronization and medication therapy management, their components and how they should be provided, which 
hampers comparability across studies. One of the main challenges for pharmacists in the US is the lack of provider status at the federal 
level. This means that pharmacists are not allowed to use existing fee-for-service health insurance billing codes to receive 
reimbursement for non-dispensing services. In addition, despite there being regulatory infrastructure in multiple states, the extent of 
service implementation is either low or unknown. Research found that pharmacists face numerous barriers when providing some of 
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HEALTHCARE DELIVERY IN THE US 
The United States (US) has a population of approximately 
330 million people from diverse backgrounds and cultures.1 
The US spends nearly 17% of its gross domestic product 
(GDP) on healthcare at over USD 10,000 per capita, which is 
twice the average compared to other developed countries.2 
Yet, the US is among the worst performers compared to 
other developed countries in key health outcomes, 
including life expectancy at birth, infant mortality, safety 
during childbirth, and unmanaged chronic conditions like 
asthma and diabetes. 
The US is one of the few developed countries without 
universal healthcare coverage; it does not have a single 
payer healthcare system or a national pharmaceutical 
benefits scheme/plan. The healthcare system includes a 
mix of public, private, nonprofit, and for-profit insurers, 
healthcare institutions and organizations, and providers. 
Modern healthcare coverage in the US began in the 1920s 
when hospitals offered pre-paid services to individuals, and 
a group of teachers in Dallas, Texas joined the first 
employer-sponsored hospitalization plan in 1929. During 
World War II, employer-sponsored health insurance 
became more popular in response to freezes on wage 
increases by the federal government. Employers could 
provide non-wage benefits (e.g., health insurance, sick 
leave) which were considered tax exempt, instead of 
increasing wages. Today, half of Americans receive health 
insurance coverage from their employer.3 
The first major step toward government-sponsored 
healthcare coverage came with an amendment to the 
Social Security Act in 1965, which created Medicare and 
Medicaid and provides healthcare benefits to select groups 
of individuals. Medicare covers individuals age 65 years or 
older, those under age 65 who are disabled, and select 
disease states (e.g., end-stage renal disease), while 
Medicaid applies to eligible low-income individuals, 
pregnant women, children under 18 years of age, and those 
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with disabilities. In 1997, federal legislation increased the 
number of children covered with the Children’s Health 
Insurance Programs, also administered via Medicaid. 
Importantly, each state is responsible for administering 
Medicaid programs and providing a safety net for those 
who do not qualify for Medicaid, and this state-level 
administration results in different coverage across states. 
Medicare Part D is the federal-government program 
initiated in 2006 that subsidizes the costs of prescription 
drug coverage to Medicare enrollees via contracts with 
numerous insurance companies (Part D sponsors), and it 
was enacted via the Medicare Prescription Drug, 
Improvement, and Modernization Act in 2003.4 While 
optional, all states currently provide coverage for 
outpatient prescription drugs to categorically eligible 
individuals, as well as most other enrollees.5 
Yet, given the nearly 46.5 million individuals that remained 
uninsured in 2010, the Patient Protection and Affordable 
Care Act (ACA, also known as “Obama care”) was passed in 
2010 and implemented in 2014 to expand healthcare 
coverage.6 The ACA created health insurance exchanges, or 
marketplaces, where low- and middle-income individuals 
could purchase their own insurance and receive 
government subsidies to offset the costs. States also 
received additional federal funding if they agreed to 
expand eligibility for Medicaid; however, not all states took 
advantage of this. Young people can also remain covered 
under their parent’s plan until age 26.7 Debate continues in 
the US regarding the role of government in providing 
healthcare insurance. 
Demand on the US healthcare system has led to a 
significant expansion of jobs in healthcare. Between 2006 
and 2016, jobs in healthcare settings increased by 20%, 
compared to only 3% job growth in the general economy.8 
The job growth has been primarily in personal care aides, 
registered nurses, nursing assistants, and home health 
aides, likely due to the rapidly aging population in the US. 
Physician shortages, especially in primary care, are a key 
issue in the US with a projected shortage between 21,400 
and 55,200 by 2033.9 In response, there has been a sharp 
increase in the number of nurse practitioners in the US, 
which are now approaching 300,000.10 Likewise, the 
number of physician assistants is increasing with expected 
job growth of 30% through 2028. With full prescribing 
privileges (unlike pharmacists), nurse practitioners and 
physician assistants are well positioned to fill gaps in the US 
primary care system. 
The projected outlook for pharmacists in the US is widely 
debated. The optimistic outlook suggests that evolving 
practice roles for pharmacists will create new opportunities 
for employment in direct patient care roles. This is evident 
by the increased demand for specialty trained pharmacists 
to work in health systems and clinics.11 On the other hand, 
there is no doubt that the exponential growth in the 
number of graduating pharmacists provides increased 
supply and that overall demand for pharmacists is 
shrinking, especially in the traditional community pharmacy 
sector. This can largely be due to losses of revenue, 
attributable to decline in reimbursement for dispensing 
medications and lack of significant reimbursement for 
clinical services. The US Bureau of Labor Statistics projects 
0% growth for pharmacists through the year 2028.12 The 
surplus of US pharmacists is largely related to the 38% 
increase in the number of pharmacy schools and 48% 
increase in the number of graduates over the past decade. 
It is possible, however, that this issue may correct itself as 
the mean number of applications per pharmacy school has 
declined over 50% in the past decade.13 
Primary care in the US 
Primary care in the US is delivered by three medical 
specialties: family medicine, general internal medicine, and 
general pediatrics. Additionally, other non-physician 
primary care providers (e.g., registered nurses, nurse 
practitioners, physician assistants, pharmacists) provide 
care alongside physicians.14,15 To further the objective of 
improving primary care, the American Academy of Family 
Physicians proposed the Health Care for All framework 
whose goal is to “ensure healthcare coverage for everyone 
in the United States through a foundation of 
comprehensive and longitudinal primary care”.16  
Since the passage of the ACA, there has been a shift toward 
transforming primary care to provide patient-centered, 
coordinated, comprehensive care focused on providing 
proactive, rather than reactive, population health 
management. One such approach is the patient-centered 
medical home (PCMH) which facilitates partnerships 
between individual patients, their families, and their 
personal physicians.17 The main principles of the PCMH 
outlined by the Agency for Healthcare Research and Quality 
are that: 1) it provides comprehensive care by a 
multidisciplinary team being accountable for meeting 
physical and mental healthcare needs; 2) it is patient-
centered, in that it considers the patients’ and their 
families’ unique needs, culture, values and preferences, 
and it promotes patients’ involvement in their care and 
disease management; 3) care is coordinated or integrated 
across specialty care, hospitals, home healthcare, and 
community services and supports, especially during 
transitions of care; 4) it offers accessible services wherein 
urgent needs are addressed, hours of operation are 
expanded, a member of the care team is available 
electronically or via the telephone, and there are 
alternative methods of communication such as email and 
telephone; 5) it is committed to quality and safety by 
engaging in performance measurement and continuous 
quality improvement, and adopting a population health 
management approach to care. In the PCMH model, 
payment recognizes patient-centered care management 
work beyond face-to-face visits, supports the use of health 
information technology for quality improvement, 
recognizes remote monitoring of clinical data using 
technology, allows additional payments for achieving 
quality improvement measures, and allows practices to 
share in savings generated from reduced hospitalizations.18  
Another approach to improve primary care delivery is 
through accountable care organizations (ACOs), which are 
groups of providers who share the joint responsibility for 
the costs and quality of care provided to an assigned group 
of Medicare patients.19 In addition to receiving 
reimbursement based on the traditional fee-for-service 
model, ACOs are eligible to voluntarily participate in the 
Centers for Medicare & Medicaid Services (CMS) Shared 
Savings Program, a program that focuses on value and 
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patient outcomes, rather than the number of encounters or 
procedures. As of January 1, 2020, there were 517 ACOs 
participating in the Shared Savings Program that provided 
care to 11.2 million (16.5%) Medicare beneficiaries.20 
The PCMH and ACO are complementary approaches to 
reformed care delivery. Despite notable progress in the 
past years, not all primary care in the US is provided 
through PCMH and ACOs. There are still many independent 
primary care physician practices and large health systems 
that do not provide care by either of these models. 
Finally, primary care is also provided in an array of other 
clinics focused on specific populations. Federally qualified 
health centers (FQHCs) are community-based health 
centers that provide primary care in underserved areas.21 
The Indian Health Service provides care in federal facilities 
to American Indian and Alaska native peoples.22 As well, 
the Veterans Health Administration serves about 9 million 
veterans yearly.23 Each of these systems is funded by the 
federal government. In addition, many communities also 
have free clinics that use volunteer/staff to provide 
healthcare services to disadvantaged individuals.24 
In summary, primary care is provided in many different 
types of clinics and the providers are paid from numerous 
sources. Three medical specialties, advanced practice 
providers, and other clinicians support the delivery of 
primary care, and there is no single model of practice or 
reimbursement. 
 
COMMUNITY PHARMACY IN THE US 
Community pharmacy in the US is comprised of a number 
of sub-types of practice settings including independent, 
traditional chain, supermarket, and mass merchant 
pharmacies (Figure 1). The National Community 
Pharmacists Association (NCPA) reported that there were 
61,800 community pharmacies in the US in 2018.25 Of the 
314,300 pharmacists in the US in 2018, more than 135,000 
(43%) worked as community pharmacists.26 Substantial 
differences in the number of pharmacies by county and 
region of the country have been identified with counties 
possessing the highest density of pharmacies per 
population having nearly three times as many pharmacies 
compared to those with the lowest density of 
pharmacies.27 Thus, where a patient lives in the US greatly 
impacts their access to community pharmacy services. 
Some pharmacies are able to generate revenue via clinical 
services (described below), but the primary business model 
for community pharmacies continues to focus on 
dispensing prescription medications to patients. In 2019, 
almost 3.8 billion prescriptions were filled in US 
pharmacies.28 While the majority (about 1.9 billion) were 
paid for by commercial insurers, which includes some 
government programs like the Children’s Health Insurance 
Program, Veterans Administration, and Indian Health 
Service, approximately 1.67 billion prescriptions were paid 
for, at least in part, by either Medicare or Medicaid, with 
patients being responsible for a co-payment.28 Payers’ 
coverage of prescriptions varies greatly across community 
pharmacy sub-type.25 In 2019, prescription dispensing 
revenues in the US reached a record USD 446 billion, with 
the top seven dispensing pharmacies (i.e., CVS Health, 
Walgreens Boots Alliance, Cigna, UnitedHealth Group, 
Walmart, Kroger, and Rite Aid) accounting for about 70% of 
the market.29 Detailed data from 2018 showed that 
independent pharmacies represented a USD 75.8 billion in 
prescription revenue, while CVS represented USD 102 
billion, followed by the Walgreens Boots Alliance at USD 
74.4 billion, Walmart at USD 20.9 billion, Kroger at USD 
13.4 billion, and Costco at just USD 2.6 billion.30 
In the US, medications are typically dispensed inside 
prescription vials or bottles that are filled at the pharmacy 
from bulk containers, rather than in individual blisters 
within boxes sold by the pharmaceutical industry, as is the 
case in Europe. Thus, the primary role of pharmacy 
technicians is to fill prescriptions and label medications in 
prescription bottles that the pharmacist then verifies. A 
growing body of literature supports expanding the role of 
technicians to administrative roles such as managing 
patient appointments, collecting comprehensive 
medication histories, and collecting clinical data to be 
reported to the pharmacist.31 The Pharmacy Technicians 
Certification Board provides national standards for 
technicians. Regulations and requirements for certification, 
registration, and licensure vary by state. To date, 24 states 
require pharmacy technicians to attain national 
certification, either as a requirement to be registered or 
licensed, or to perform certain duties.32 
Policy considerations affecting community pharmacy in 
the US 
One of the most significant barriers to advancing 
Figure 1. Sub-types of community pharmacies in the US and estimates for each type based on NCPA data
25 
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community pharmacy practice in the US is the current 
payment structure. When the Social Security Act was 
passed in 1965, pharmacists were omitted from the 
definition of healthcare providers, resulting in pharmacists 
not being able to be paid by the Federal government for 
most services under Medicare Part B (i.e., while Medicare 
Part A covers hospital care, Medicare Part B covers services 
provided by physicians and other providers in outpatient 
settings). Because other payers generally follow Medicare 
payment policies, there are limited opportunities for 
pharmacists to receive reimbursement from public, private 
or commercial payers. Being recognized by CMS as a 
provider would enable pharmacists to use existing fee-for-
service health insurance billing codes when they provide 
non-dispensing services. Some exceptions exist for specific 
services provided to Medicare beneficiaries in Part D 
programs, such as medication therapy management (MTM) 
and immunizations. 
Achieving this objective requires working with the federal 
government to develop and pass legislation to add 
pharmacists to its list of providers.33 To that end, 11 
pharmacy organizations and other stakeholders are 
working together towards achieving provider status for 
pharmacists and studying possible options for legislative 
language that are primarily focused on amending the Social 
Security Act.34 Given the myriad pharmacy organizations in 
the US prioritizing their own agenda (e.g., American 
Pharmacists Association, American College of Clinical 
Pharmacy, American Society of Health-System Pharmacists, 
Academy of Managed Care Pharmacy, American Society of 
Consultant Pharmacists, among others), having a unified 
voice for the pharmacy profession is a challenge. The fact 
that 11 organizations have united efforts to advocate for 
provider status underscores the importance of such 
legislation for the profession. 
Passing such federal legislation is likely to take considerable 
time, and several individual states (e.g., California, 
Washington) have passed provider status legislation for 
pharmacists, though they continue work on how these 
statutes will be implemented.35,36 Achieving provider status 
at the state-level, in theory, may allow pharmacists to 
negotiate reimbursement for services directly with 
insurance companies; however, payment may still not 
follow provider status recognition at the state level. 
Community Pharmacy Enhanced Services Network 
The Community Pharmacy Enhanced Services Network 
(CPESN) is a clinically integrated network of community 
pharmacies (mostly independent), that resulted from the 
expansion of the Community Care of North Carolina in 2014 
with funding from a 3-year grant by the Centers for 
Medicare and Medicaid Innovation (CMMI). The goal was 
to provide a structure for community pharmacies to expand 
primary care efforts, as well as a means to negotiate 
reimbursement for services with payers as a group.37,38 This 
model has now spread to 44 states and includes 2,700 
community pharmacies that offer enhanced services for 
high-risk patients. The core services that pharmacists are 
required to offer to be a part of the network include 
medication reconciliation, medication synchronization, 
immunizations, comprehensive medication reviews, face-
to-face access to a pharmacist, and creating a 
comprehensive medication list. Additional enhanced 
services provided by select pharmacies comprise: 24-hour 
emergency services, collection of vital signs, home 
delivery/home visits, tobacco cessation program, durable 
medical equipment, point-of-care testing, long-acting 
injections, naloxone dispensing, nutritional counseling, and 
specialty medication compounding.39 To the best of our 
knowledge, no public information exists regarding the 
percentage of pharmacies providing each of the services 
and the reimbursement rates negotiated (if any) for each 
service across states. Several challenges were reported by 
pharmacists in the North Carolina CPESN offering 
medication management services related with initiating 
services, accessing internal and external information, 
documenting, among others. This same study found that 73 
(59.3%) of the 123 participating pharmacies did not 
complete service requirements within the first 3 months.40 
In 2019, the Community Pharmacy Foundation and CPESN 
partnered to fund the Flip the Pharmacy initiative which 
aims to transform community pharmacy practice, moving 
away from point-in-time and prescription-level to 
longitudinal and patient-level care processes and business 
models.41 Six transformation domains comprise the 
initiative, namely: leveraging the appointment-based 
model, improving patient follow-up and monitoring, 
developing new roles for non-pharmacist support staff, 
optimizing the utilization of technology and electronic care 
plans, establishing working relationships with other care 
team members, and developing the business model and 
expressing value.
42
 The initiative is currently underway, 
thus limited evidence regarding its impact on community 
pharmacy processes, volume and payment of services, or 
patient outcomes exists.43 The ultimate goal is to gather 
evidence of the contribution of community pharmacists to 
improved patient care to serve as a means to negotiate 
reimbursement for pharmacist services with payers. 
Pharmacy education and training in the US 
Since 2000, the recognized professional degree that can be 
obtained from schools of pharmacy in the US is the 
Pharm.D. (doctoral degree). However, there remain a 
significant number of practicing pharmacists who were not 
trained at the doctoral level and have bachelor’s or 
master’s degrees.44 The 2016 American Council on 
Pharmaceutical Education’s set of educational standards 
were designed to ensure that all graduating pharmacists 
were prepared to contribute meaningfully to patient-
centered care and interdisciplinary team practice, use 
evidence-based practice, apply quality improvement 
strategies, and utilize informatics.44 While community-
based pharmacy residencies are not currently required, the 
number of such residencies has grown in the last 20 years 
to more than 130 accredited post-graduate year 1 (PGY1) 
programs.45 However, this growth has not kept pace with 
demand by student pharmacists or professional 
organizations such as the American College of Clinical 
Pharmacy, which previously advocated that starting in 2020 
all pharmacists involved in direct patient care complete an 
accredited residency.45 
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Integration of community pharmacy and primary care 
Pharmacists are integrated into primary care in a number 
of important ways, which continue to evolve over time. In 
support of better coordination between community 
pharmacy and primary care, the Centers for Diseases 
Control and Prevention (CDC) Division for Heart Disease 
and Stroke Prevention developed a practitioner and a 
pharmacist guide for “Creating Community-Clinical Linkages 
Between Community Pharmacists and Physicians” in 
collaboration with the American Pharmacists Association 
and the American Medical Association.46,47 Community-
clinical linkages are defined as connections between the 
community, clinics, and other settings where primary care 
is provided to improve population health.46 The pharmacist 
guide provides a framework called LINKAGE outlining how 
community pharmacists and physicians can develop 
community-clinical linkages.47 Suggested activities to be 
performed by both parties as part of these linkages include: 
pharmacists conducting health assessments and referring 
patients to physicians for diagnosis or treatment; 
pharmacists triaging patients with medication-related 
problems or new/worsened health conditions into primary 
care; and physicians referring patients to pharmacists for 
medication and chronic conditions management.47 
One way for community pharmacists to provide services 
and be reimbursed is by extending beyond the walls of the 
pharmacy and establish collaborations with primary care 
clinics. An example of such a model is pharmacists from an 
independent community pharmacy in the state of North 
Carolina providing services at an independent primary care 
clinic three days a week.
48,49
 Over and above improving 
patient outcomes, this service also gained the clinic an 
additional USD 16,920 in annual reimbursement.49 
Pharmacists provide chronic care management services 
(i.e., services aiming to improve health outcomes by 
enhancing care coordination for patients with multiple 
chronic conditions) to Medicare beneficiaries, reimbursable 
since January 2015 via the Medicare fee-for-service 
program.50 The goal is to help the primary clinic achieve the 
quality measures set by CMS, while also arranging a way for 
both parties (physician and pharmacists) to be reimbursed, 
even if billing is under the physician’s fee schedule. This 
model is by no means widespread in the US and requires 
collaboration with a provider.50 
Primary care is also moving inside pharmacies. Several 
community pharmacy chains and mass merchants have 
opened walk-in clinics inside their stores as a means to 
increase access to care. For example, CVS has co-located 
Minute Clinics that provide walk-in care for minor illnesses, 
minor injuries, skin conditions, travel health, vaccinations 
and injections, wellness and physicals, women’s services, 
and screenings and monitoring. Cost of services can be 
covered by insurance plans or paid out-of-pocket. 
Treatment for minor illnesses, minor injuries, skin 
conditions, wellness and physicals, and screenings and 
monitoring cost between USD 99-139/visit; cost for travel 
health related items ranges between USD 59-142; women’s 
services cost between USD 59-250; and vaccinations and 
injection administration between USD 50-250.51 Care is 
provided by nurse practitioners and physician assistants 
(not pharmacists) to both adults and children.52,53 The CEO 
of CVS Health has publicly stated that “retailization of 
healthcare” will continue to evolve, with service 
convenience being a top priority.54 Walgreens had a similar 
arrangement up until 2019, but decided to outsource the 
service to VillageMD, a group of primary care physicians, in 
July 2020. They plan to open 500-700 “Village Medical at 
Walgreens” physician-led primary care clinics in more than 
30 US markets in the next five years. The press release 
mentions that pharmacists will be integrated as a critical 
member of the VillageMD’s multi-disciplinary team, but no 
further details are provided.55 
Pharmacist prescriptive authority 
In the US, pharmacists who are able to prescribe, monitor, 
and adjust medications independent of or in collaboration 
with physicians can generally provide associated clinical 
services. The National Alliance of State Pharmacy 
Associations (NASPA) is a trade association that tracks 
pharmacy legislation and regulations across all 50 states 
and the District of Columbia.
56
 NASPA and the Idaho State 
Board of Pharmacy proposed a framework to characterize 
Figure 2. Summary of available practice models adopted by states that allow pharmacists to prescribe in the United States  
(CPAs, collaborative practice agreements) 
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existing models of pharmacist prescriptive authority along a 
continuum from most restrictive to least restrictive (Figure 
2).57 At present, 49 states and the District of Columbia have 
passed legislation that allows pharmacists to prescribe 
medications under CPAs, standing orders, or statewide 
protocols. 
In a collaborative prescribing model, pharmacists and 
prescribers create formal relationships through the 
establishment of collaborative practice agreements (CPAs) 
wherein the latter grant prescriptive authority to the 
former.58,59 CPAs can be patient-specific (i.e., individual 
patients or a collaborating prescriber’s patient panel) or 
population-specific (i.e., categories of patients). While 
population-specific CPAs are commonly used for acute care 
(e.g., treatment of influenza in patients with certain 
characteristics that do not meet criteria for automatic 
referral), both patient- and population-specific CPAs are 
established for chronic disease management (e.g., 
diabetes, hypertension, hyperlipidemia, asthma).57 
Autonomous prescribing can occur via statewide protocols 
or unrestricted category-specific prescribing. In these 
situations, CPAs are not required to be in place for 
pharmacists to prescribe; however, pharmacists are still 
responsible for coordinating care with the primary care 
provider. Statewide protocols are set by an authorized 
body or state government (e.g., Board of Pharmacy, 
Department of Health) and allow pharmacists to prescribe 
medications that are intended for preventive care or for 
acute or self-limiting conditions that require a limited 
process to diagnosis. The scope of statewide protocols is 
generally narrow and often arises in response to a public 
health crisis. Any pharmacist who fulfills the requirements 
specified in the protocol is authorized to prescribe without 
supervision from a collaborating physician, unlike CPAs.57 
Unrestricted category-specific prescribing applies to a 
limited range of medications for which no specific diagnosis 
is needed. Instead of following a state-derived protocol, 
states refer pharmacists to other authority documents, 
such as practice guidelines, to guide prescribing. 
Autonomous and collaborative prescribing supplement 
each other, rather than being mutually exclusive.57  
A standing order is a statewide prescription issued by a 
state designated prescriber under which pharmacists are 
allowed to fill a prescription to dispense a product (e.g., 
naloxone, smoking cessation products). In this model, 
pharmacists are not the prescribers.  
Community pharmacy services 
As described above, pharmacy practice legislation varies 
across all 50 states and the District of Columbia. Likewise, 
reimbursement for specific services also differs at the state 
level, unless reimbursement is based on federal legislation, 
as is the case of services for Medicare beneficiaries. In the 
US, there is a history of pharmacy services innovations, but 
state fragmentation and the lack of a single payer system 
and a single vision and voice for the pharmacy profession 
prevent scaling these innovations at the national level. 
Chain pharmacies play a pivotal role in scaling service 
innovation in community pharmacy beyond dispensing 
services through counseling, MTM services, and several 
disease state management initiatives.60,61 Due to their 
dissemination across the country, scale up of services is 
maximized. For example, reports demonstrate chain 
pharmacies positioning themselves to meet demand for 
convenience in offering immunization services.62 However, 
work in a busy chain pharmacy can lead to pharmacist burn 
out, which in turn compromises patient safety.63,64 
The services described below represent the mainstream 
services that pharmacists currently provide and, in 
particular circumstances, for which they can obtain 
reimbursement (Table 1). Due in part to the fragmented 
nature of the healthcare system in the US, it is not currently 
possible to report the extent to which these services are 
provided. Existing evidence usually derives from research 
studies that academics conduct with data obtained from 
either local Boards of Pharmacy or state-wide surveys, the 
latter usually limited by a low response rate. More recent 
reports of MTM have used Medicare Part D claims to 
examine some services. 
Immunizations 
All 50 states and the District of Columbia have legislation 
allowing pharmacists (and student pharmacist interns 
operating under the supervision of the pharmacist) to 
administer immunizations. States allow vaccine 
administration via any of the prescribing mechanisms 
described above, except one (Alabama) which only allows 
vaccine administration by prescription. The types of 
vaccines that pharmacists can administer and the minimum 
age of patients to whom they are allowed to administer 
also vary across states. While some allow any vaccine to be 
administered to any patient regardless of age, others do 
not allow pharmacists to administer certain vaccines (e.g., 
human papillomavirus vaccine) or restrict administration to 
adults or children older than a certain age.65 Immunization 
administration in some states also extends to CDC-
recommended travel vaccinations. As of June 2020, six 
states allowed pharmacy technicians who completed 
immunization certificate training to administer vaccines 
under the direct supervision of a certified pharmacist.65 
The 2019 National Pharmacist Workforce Study reported 
that 90% of community pharmacists administered 
vaccines.66 In Westrick et al.’s study of a nationally 
representative sample of 292 community pharmacies, 80% 
reported that they had provided immunization services in 
2016, the most common vaccines being influenza, herpes 
zoster, pneumococcal 13-valent conjugate (PCV13) and 
pneumococcal polysaccharide (PPSV23).67 Pharmacy-based 
immunization services have been associated with an 
increase in the likelihood of being immunized.68 As an 
example, influenza vaccinations dispensed in community 
pharmacies increased from 3.2 to 20.9 million between 
2007 and 2013.69  
In order to bill for immunization administration, 
pharmacies need to contract with the appropriate payers 
(i.e., pharmacy benefits managers, Medicare, Medicaid, 
third-party medical plans). Pharmacies bill for both the 
product and the administration service. Administration fees 
vary between USD 15 and USD 40.70 Additionally, 
pharmacies can charge customers or private employers 
with whom they contract directly. The average direct costs 
paid per adult vaccination were shown to be lower in 
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pharmacies compared with other medical settings, likely 
because in medical settings additional billing codes can be 
applied (e.g., billing codes covering patient counseling).71 
Medication therapy management 
MTM is a service included in Medicare Part D plans that 
aims at improving medication use and reducing the risk of 
adverse events in eligible Medicare beneficiaries.72 MTM 
includes five core elements: 1) comprehensive medication 
review (CMR); 2) provision of a personal medication record; 
3) construction of a medication-related action plan 
consisting of a list of actions for patients to track progress 
for self-management; 4) intervention to address 
medication-related problems or referral to a physician or 
other healthcare professional; and 5) documentation of 
MTM services and follow-up visit.73,74 Part D plans are 
required to provide and automatically enroll in their MTM 
programs beneficiaries who meet pre-specified CMS 
criteria, namely: having multiple chronic diseases, taking 
multiple Part D medications, and being likely to incur 
annual Part D medication costs that meet or exceed a 
certain threshold every year (e.g., USD 4,044 in 2019).75 
However, 27% of MTM programs in 2019 used expanded 
eligibility requirements beyond the minimum required by 
CMS.76 MTM services may be provided by pharmacists or 
other healthcare professionals. For example, of the 649 
Part D contracts with an approved MTM program in 2019, 
100% used pharmacists to provide MTM services, 74% used 
a registered nurse, 24.5% a physician, and 15.1% a 
physician assistant (multiple selections were allowed, thus 
categories were not mutually exclusive). Beneficiary 
enrollment into MTM programs should be at least quarterly 
(47.1% of plans in 2019), but could also be every other 
month, monthly, weekly or daily. Eligible beneficiaries are 
mainly identified via medication claims data.76 
The CMR is a core element of MTM and it consists of an “an 
interactive person-to-person or telehealth medication 
review and consultation conducted in real-time between 
the patient or other authorized individual, such as 
prescriber or caregiver, and the pharmacist or other 
qualified provider and is designed to improve patients’ 
knowledge of their prescriptions, over-the-counter (OTC) 
medications, herbal therapies and dietary supplements, 
identify and address problems or concerns that patients 
may have, and empower patients to self-manage their 
medications and their health conditions”. Part D sponsors 
are required to provide a CMR at least annually or targeted 
medication reviews (TMR) quarterly. TMRs are shorter 
duration medication reviews to assess medication use, 
monitor unresolved issues, identify new drug therapy 
problems, and assess whether beneficiaries experienced a 
Table 1. Pharmacist services available in the community pharmacy setting.   
Service/Activity Availability status (date) Regulation 
level 
Reimbursement 
Immunizations  All 50 states and the District of Columbia (Jun. 2020) 
 1 state (Alabama) only by prescription (Jun. 2020) 
 6 states allow pharmacy technicians with required 
training to administer vaccines under the supervision 
of a certified pharmacist (Jun. 2020) 
State  Via contract with the appropriate 
payers (i.e., pharmacy benefits 
managers, Medicare, Medicaid, third-
party medical plans) 
 Bill payers for both the vaccine and 
administration service (varies 
between USD 15 - 40) or paid by 
patients out-of-pocket 
Medication Therapy 
Management (MTM) program 
 All 649 Medicare Part D contracts use pharmacists to 
provide MTM (2019) 
Federal  Reimbursement provided by CMS 
 Billing in 15-minute increments using 
current procedural technology codes  
Medication packaging  Implementation status unknown N/A  Paid by customers out-of-pocket or 
offered as part of a medication 
synchronization program 
Medication synchronization   22,000 community pharmacies (2015) N/A  No reimbursement. MTM billing 




 9 states and the District of Columbia (Dec. 2019) State  Reimbursement varies by state 
Point-of-care (POC) testing   All 50 states and the District of Columbia - for 
approved tests with pharmacy CLIA waiver from CMS 
(1988) 
Federal  Paid by customers out-of-pocket 








 All 50 states and the District of Columbia (Jan. 2019) 
o 17 states and the District of Columbia - statewide 
protocol/pharmacist prescribing (Jan. 2019) 
o 12 states - statewide standing order (Jan. 2019) 
o 4 states - dispense without a prescription (Jan. 
2019) 
o 17 states - standing order (Jan. 2019) 
State  Variable out-of-pocket costs 
depending on the patient’s health 
insurance 
 Pharmacist counseling not 
reimbursable 
Tobacco cessation aid 
prescribing 
 37 states (Nov. 2019) 
o 12 states - statutes or regulations allowing 
pharmacists to prescribe (Nov. 2019) 
o 17 states - prescribe under population-based 
CPAs (Nov. 2019) 
o 7 states - prescribe via autonomous prescribing 
(Nov. 2019) 
o 1 state - independent prescribing (Nov. 2019) 
State  Reimbursement varies by state 
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transition of care. CMR delivery method can be face-to-
face, over the phone or through telehealth.76 The benefits 
from obtaining a CMR include the identification of 
effectiveness and safety issues with prescribed 
medications, as well as identification of less expensive 
alternative medications for patients.77 Despite the benefits 
of CMRs, the uptake of the service is low – less than 20% of 
eligible Medicare beneficiaries in 2013 and 2014 received 
the service –, either because patients are unaware of it or 
because they perceive it as unnecessary.77-79 Data from the 
2019 National Pharmacist Workforce Study indicated that 
66.7% of respondents provided MTM services.66 
Additionally, analyses of Medicare claims data from 2014 
revealed that community pharmacies provided only 22% of 
the CMRs, with the remainder provided by either other 
types of pharmacists or other professionals.80 In 2018, the 
CDC launched a statewide initiative focused on 
implementing and evaluating evidence-based strategies to 
manage diabetes and prevent or delay onset of type 2 
diabetes in high-burden populations and communities, and 
one of the strategies proposed is to expand MTM services 
provided by pharmacists to patients with diabetes.81 
The effectiveness of MTM services remains a contested 
topic because of heterogeneity of previous studies’ 
populations, settings, and outcomes.82 In addition, 
contemporary MTM definitions found in the professional 
literature differed from the early definition in the 
regulatory reference, making meaningful evaluations over 
time difficult.83 
Reimbursement to pharmacists (and other professionals) 
rendering MTM services is provided by CMS. Billing is in 15-
minute increments using current procedural technology 
codes (specific codes used for medical billing). The initial 
15-min face-to-face assessment is reimbursed at a rate of 
USD 50 and is covered once a year per provider per 
beneficiary. Follow-up assessments of 15-minute 
increments are reimbursed at a rate of USD 25 and 
providers can bill up to seven times in a year. Additional 15-
minute increments to the two previous codes can be billed 
up to four times per provider per beneficiary per date of 
service at a rate of USD 10.84 Lack of standardization for 
documentation and billing is an important limiting factor of 
MTM programs.85 Another potentially contested aspect is 
the effectiveness of a CMR without access to the electronic 
health record (EHR). 
Medication adherence 
Similar to other countries, community pharmacists in the 
US offer services aimed at improving medication 
adherence.86,87 
Medication packaging is one such service. Packaging 
interventions significantly improved medication adherence 
in a meta-analysis of 52 studies.88 This study demonstrated 
that interventions using blister packs compared with pill 
boxes, and delivered in pharmacies compared to 
interventions delivered elsewhere were significantly more 
effective at improving adherence.88 It is unclear what 
percentage of community pharmacies in the US offer 
medication packaging services. The service is not 
reimbursed by CMS or prescription insurance plans. While 
some pharmacies may offer the service as part of their 
medication synchronization service, others may charge an 
out-of-pocket fee to customers. 
Medication synchronization is a process by which a 
patient's medications refill dates are aligned so that 
patients only come to the pharmacy once a month. Prior to 
preparing the medication, pharmacy staff call patients to 
identify whether any changes to medications occurred and 
to confirm what medications should be dispensed. This 
contributes to a higher efficiency of the pharmacy 
workflow, in addition to presenting an opportunity for 
pharmacists to perform a medication review and identify 
any therapeutic or compliance issues.89 As of 2015, this 
service was being offered by more than 20,000 chain and 
2,000 independent community pharmacies across the 
country and 66.5% of participants in the National 
Pharmacist Workforce Study reported that they offered the 
service.66,90 However, service provision varies across 
pharmacies – while some focus exclusively on the 
alignment of refill dates, others conduct an appointment-
based medication synchronization where patients meet 
with the pharmacist to discuss their medications, any 
adherence issues, or receive MTM services.91,92 
Unfortunately, the extent to which each modality occurs is 
unknown and even if it were self-reported, it is legitimate 
to expect response bias. The service itself is not 
reimbursable but it may contribute to increased monthly 
prescription volume.93 Additionally, if MTM services are 
provided with medication synchronization, the pharmacy 
receives reimbursement via the MTM billing mechanisms. 
Retrospective analyses of the service showed that 
appointment-based medication synchronization increased 
the odds of being adherent by 2 to 6 times compared to 
patients not enrolled in the service.94-96 Patients in a 
synchronization program also presented rates of 
hospitalization and emergency department visits and rates 
of outpatient visits that were 9 and 3 percent lower, 
compared to a control group obtained via propensity score 
matching.94 However, it is unclear which components of the 
service contribute to these improvements due to the lack 
of a consensus definition of medication synchronization.92 
Hormonal contraception 
As of December 2019, nine states and the District of 
Columbia had statewide authority for autonomous 
pharmacist contraception prescribing.97 Each statewide 
authority has different prescribing protocols, patient age 
limitations, contraceptive formulations allowed (e.g., oral, 
patch), and pharmacist training requirements.97 Many 
included a patient self-screening assessment, blood 
pressure measurement, documentation requirements, and 
patient education materials in the prescribing procedure.97 
Reimbursement exists on a state-by-state basis. For 
example, in the state of Oregon, certified pharmacists 
prescribe hormonal contraception and are reimbursed by 
Medicaid and private payers at the same rate as physicians 
and nurse practitioners for both the product and the 
assessment.98 Since April 2019, California’s State Medicaid 
program (Medi-Cal) reimburses pharmacist services 
furnishing hormonal contraception at a rate of 85% of the 
fee schedule for physician services.99 A time and motion 
study conducted in community pharmacies in the state of 
Oregon found that pharmacists spent approximately 18 
minutes to screen a patient for eligibility, document the 
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encounter, and provide a written prescription for 
contraceptives in an uncomplicated patient.100 A 
descriptive study of 391 supermarket-based pharmacies in 
California and Oregon revealed that 1970 service visits 
resulted in birth control prescriptions by 381 pharmacists, 
95.7% of which were for the pill, 2.1% for the vaginal ring, 
1.6% for a transdermal patch and 0.1% for an injectable.101 
In other studies, pharmacists described time constraints, 
lack of access to EHRs, lack of reimbursement, additional 
training needs, and liability concerns as potential barriers 
to prescribing contraception.102-104 State practice laws, 
workflow design, and perceived barriers by pharmacists will 
need to be addressed to fully expand patient access to 
pharmacist-prescribed hormonal contraception. 
Point-of-care testing 
Point-of-care (POC) testing, such as blood glucose, 
hemoglobin A1c, cholesterol and international normalized 
ratio testing are some of the available community 
pharmacist-provided services and may be included under a 
CPA. In order to perform POC tests, pharmacies must 
obtain a certificate of waiver from CMS to perform a 
Clinical Laboratory Improvement Amendment (CLIA)-
waived test.105 A CLIA-waived test is designed for screening, 
monitoring, or diagnosis outside of a laboratory setting and 
are used within a community pharmacy setting.106 
In recent years, POC testing has expanded beyond glucose 
and cholesterol (Table 2). Community pharmacists 
providing POC testing for group A streptococcus and 
influenza under a CPA increased access by administering 
POC tests outside of normal clinic hours, conducting tests in 
patients without a primary care provider, and providing 
appropriate medication based on test results.107-109 
Similarly, POC testing for human immunodeficiency virus 
and hepatitis C was provided by trained community 
pharmacists.110-112 The availability of these tests is not 
widespread and patient awareness, willingness to receive, 
and payment mechanisms for community-based POC 
infectious disease testing remain a concern.113 While POC 
testing may be an important means to screen patients and 
provide care, the business model for it must be developed. 
Opioid reversal agents 
In response to the opioid epidemic in the US, efforts to 
increase access to naloxone in community pharmacies have 
been widespread. Each state and the District of Columbia 
has varying levels of how pharmacists may prescribe or 
dispense naloxone, ranging from a statewide protocol, 
including pharmacist prescribing authority, to the ability to 
dispense without a prescription.116,117 In the 2019 National 
Pharmacist Workforce Study, 72.2% participants reported 
dispensing naloxone.66 Despite 57% pharmacists working in 
community settings feeling confident recommending 
naloxone, only 28.3% felt confident administering it.66 A 
greater proportion of mass merchandiser (76.6%) and large 
chain (63.3%) pharmacies dispense naloxone via a standing 
order compared to independent and small chain 
pharmacies. The latter dispense naloxone more frequently 
based on a prescription order (44.4% each).66 
An analysis of community pharmacy records revealed that 
naloxone dispensing increased from 1,282 prescriptions 
(0.4 per 100,000) in 2012 to 556,847 (170.2 per 100,000) in 
2018. Individuals with commercial insurance represented 
the largest percentage of dispensed naloxone prescriptions 
in 2018 (51.1%), followed by Medicare (35.9%), Medicaid 
(10.7%), and self-pay (2.4%). A majority (42.3%) of 
prescriptions did not require out-of-pocket costs, while 
24.5% required out-of-pocket costs of less than USD 10.00, 
21.9% between USD 10.01–50.00, and 5.8% over USD 
50.00. Counties with high naloxone-dispensing also had 
more high-dose opioid dispensing rates, higher drug 
overdose deaths rates, higher potential buprenorphine 
treatment capacity, and higher rates of Medicaid 
enrollment. Micropolitan and rural counties were less likely 
to be a high naloxone-dispensing county compared to 
metropolitan ones. However, in this study, pharmacists 
were grouped under “other” specialty prescribers, thus 
limiting the ability to determine the amount of pharmacist-
provided naloxone.118 Differences in state practice laws, 
required pharmacist training, pharmacist time, pharmacist 
confidence in naloxone prescribing, inadequate pharmacist 
reimbursement, and patient out-of-pocket costs present 
current challenges to widespread adoption of naloxone 
dispensing.119,120 
Smoking cessation 
Prescription of tobacco cessation therapy can be achieved 
through the establishment of population-based CPAs, 
standing orders, statewide protocols, or independent 
prescribing. In the latter two cases, pharmacists not only 
prescribe but are also able to bill the patient’s insurance for 
any covered smoking cessation services in addition to the 
prescription medication dispensed (reimbursement 
variable).121 For example, in California, the Medicaid 
program (Medi-Cal) covers smoking cessation services at 
85% of the physician’s fee.99 The products covered under 
statewide protocols vary across states, with some including 
varenicline and bupropion, in addition to non-prescription 
and prescription nicotine replacement therapy products. 
Pharmacists must meet minimum education requirements 
to engage in autonomous prescribing of tobacco cessation 
products.122 Provision of this service is sporadic, despite 
legislation being passed in many states. 
 
FUTURE DIRECTIONS IN COMMUNITY PHARMACY 
IN THE US 
Community pharmacy practice in the US contains multiple 
stakeholders whose interests often compete. To discuss the 
future of community pharmacy in the US we will use 
Donabedian’s structure, process, outcomes framework.123 
Structure 
Table 2. Point-of-care tests available in community pharmacy in 
the United States* 
Blood glucose 
Cholesterol 
Group A Streptococcus  
Helicobacter pylori 
Hemoglobin A1c 
Hepatitis C Virus 
Human Immunodeficiency Virus 
Influenza 
International Normalized Ratio 
Pharmacogenetics 
*Note that this is not a complete list of all possible tests. 
Adapted from information provided by NCPA
105
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One of the most significant barriers is the current payment 
structure and pharmacists not being recognized as 
providers by CMS, as discussed above. While achieving 
provider status is an important step for the profession to 
bill under fee-for-service, it is also important to 
acknowledge a growing shift from this model to pay-for-
performance healthcare reimbursement. Similar to other 
jurisdictions around the world, the US is facing precipitous 
increases in healthcare costs. One method for beginning to 
address these increases is shifting incentive structures 
away from the quantity of services provided to one focused 
on the quality of services provided. Quality measures have 
been proposed and adopted at multiple levels of the 
healthcare system including hospitals, physicians, nursing 
homes and health plans, to drive improvement, inform 
consumers, and determine payment. Of particular 
relevance to community pharmacy is the Medicare Star 
Ratings program which evaluates the quality of Medicare 
prescription drug plans on a 5-star system where higher is 
better.124 There are currently five active medication-related 
measures, which have been developed in collaboration 
with the Pharmacy Quality Alliance, whose mission is to 
optimize health by advancing quality medication use.125 The 
five measures are: 1) medication adherence (via calculation 
of the proportion of days covered) for 1a) diabetes, 1b) 
hypertension, and 1c) cholesterol medications; 2) CMR 
completion rate as part of the MTM program; and 3) statin 
use in persons with diabetes.126,127 Though not specific to 
community pharmacy, community pharmacists have the 
potential to impact all these measures through many of the 
services outlined previously. Importantly, health plans in 
select states have started paying bonuses to high 
performing pharmacies (i.e., those who positively impact 
medication-related quality measures) and including them in 
preferred pharmacy networks, meaning that patients who 
utilize these pharmacies will have reduced or no co-pays for 
their prescriptions.128 Although value-based 
reimbursement continues to evolve, it does present 
community pharmacy with a unique opportunity to build a 
new community pharmacy practice model. 
Another significant barrier, but also a potential 
opportunity, comes from needed improvements in access 
to technologies such as EHRs, use of mobile health 
applications, and telemonitoring.129,130 Success in accessing 
patients’ EHRs from a community pharmacy setting to help 
coordinate care and communicate with other providers is 
achievable, though would require collaborations across 
multiple health systems and EHRs.131 Access to EHRs helps 
community pharmacists gain access to the current 
medication list, doses, and laboratory results to monitor 
medication effectiveness and disease control or 
progression.132 The use of mobile health apps for sharing of 
health information between the community pharmacy, the 
patient, and other healthcare providers is growing. For 
instance, the MEDIvate iOS smartphone application using 
cloud architecture allows patients to scan a vaccine 
prescription QR code to import their vaccine data and 
vaccine information into the app.133 
Failing to adequately address these barriers will leave 
community pharmacy open to a substantial threat from 
disruptors such as Amazon. In addition to its recent 
acquisition of the online pharmacy PillPack, Amazon’s 
operations are specifically designed for efficiency, have 
extensive transportation networks, and can leverage the 
presence of Whole Foods (a groceries store) to provide 
great customer experience.134,135 Amazon can offer 
substantial discounts to cash-paying customers because of 
its size and will present a viable alternative to the 
employers searching for pharmacy benefit plans for their 
employees.134 Finally, it is also nearly prepared to meet the 
needs of the Drug Supply Chain Security Act, which will 
come into effect in 2023, that requires that all prescription 
medications be traceable from manufacturer to patient.134 
Process 
The success of structural adaptations will only be achieved 
if corresponding adjustments are made to processes taking 
place within the community pharmacy. To begin, all 
technical duties should be transitioned to pharmacy 
technicians. There is growing evidence supporting 
technicians’ participation in MTM sessions, serving as 
pharmacist extenders, and completing tech-check-tech 
dispensing.136,137 Some states have passed legislation 
allowing technicians to provide some immunizations.138 
Before these tasks can be given entirely to technicians, the 
laws governing technician practice across the country must 
be standardized to ensure adequate levels of training and 
competency.137 
The COVID-19 pandemic has also further accelerated the 
process of giving and receiving care via telehealth.139 This 
represents an opportunity for community pharmacy to 
transition some services to this delivery format to save 
patients time and pharmacy resources. For example, it 
could be a means to standardize the provision and increase 
uptake of MTM among Medicare Part D plan beneficiaries. 
As technicians release pharmacists’ time for clinical duties 
and new opportunities for the provision of care via 
telehealth are adopted, the profession should acknowledge 
and lessen the impact of “community pharmacy practice 
inertia”, characterized by a reliance on outdated protocols 
and practices in the face of new evidence.140 Despite 
various legislative advances, uptake of community 
pharmacist services is generally low across states, speaking 
further to the need to address both structure and process 
aspects.  
Outcome 
Once structure and process adjustments have been made, 
community pharmacists can focus on service expansion and 
clinical, humanistic and economic outcomes. A common 
criticism to the pharmacy practice literature relates to the 
poor and inconsistent intervention reporting.141-144 As 
mentioned above, a challenge with MTM and medication 
synchronization is the lack of standardized definitions and 
process of how these services are provided across multiple 
studies.82,83,92 In order for services to be integrated in 
routine community pharmacy practice and sustained over 
time, it will be helpful to draw from the implementation 
science discipline. Implementation science focuses on 
methods to “promote the systematic uptake of research 
findings and other evidence-based practices into routine 
practice”.145 Implementation science emphasizes 
systematic thinking about healthcare delivery and has 
developed numerous frameworks for, not only rethinking 
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practice change implementation, but also for guiding 
ongoing data collection and monitoring.146 These data will 
be as equally important as patient outcomes as current and 
future practice scope expansion legislation is passed. 
 
CONCLUSION 
Community pharmacy is the US offers some clinical services 
to support primary care, but the business model retains a 
focus on dispensing. Chain pharmacies (and potentially 
pharmacies within CPESN) offer important opportunities to 
scale clinical services nationwide. Yet, the delivery of 
medications to homes via incredibly efficient modes – 
whether Amazon or automated transportation – offers 
significant opportunity beyond dispensing for helping 
healthcare providers and patients obtain the best 
outcomes from medications. When we overcome structural 
barriers to care such as limited reimbursement and lack of 
coordination with the EHR, then community pharmacists 
will be able to adapt their processes of care to achieve 
improved patient outcomes. 
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